Targeting IL-6 signaling could, therefore, represent a potential therapeutic strategy to modulate antibody responses.IMPORTANCEThe difficult-to-treat MABS infection is a major clinical problem in Asian patients with adult-onset primary immunodeficiency associated with anti-IFN-γ autoantibodies. The gene discussed is IL6; the disease is inborn error of immunity.